---
document_datetime: 2025-11-23 08:50:22
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/raplixa.html
document_name: raplixa.html
version: success
processing_time: 0.087841
conversion_datetime: 2025-12-27 09:45:16.483187
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Raplixa

[RSS](/en/individual-human-medicine.xml/66490)

##### Withdrawn

This medicine's authorisation has been withdrawn

human fibrinogen / human thrombin

Medicine

Human

Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Raplixa](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 19 March 2018, the European Commission withdrew the marketing authorisation of Raplixa (human fibrinogen / human thrombin) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Mallinckrodt Pharmaceuticals Ireland Limited, which notified the European Commission of its decision not to market the product in the EU for commercial reasons.

Raplixa was granted marketing authorisation in the EU on 19 March 2015 as supportive treatment where standard surgical techniques are insufficient for improvement of haemostasis. The marketing authorisation was initially valid for a 5-year period.

The European Public Assessment Report (EPAR) for Raplixa is updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

Raplixa : EPAR - Summary for the public

Reference Number: EMA/55672/2015

English (EN) (546.23 KB - PDF)

**First published:** 04/05/2015

**Last updated:** 10/10/2018

[View](/en/documents/overview/raplixa-epar-summary-public_en.pdf)

Raplixa : EPAR - Risk-management-plan summary

English (EN) (571.38 KB - PDF)

**First published:** 04/05/2015

**Last updated:** 10/10/2018

[View](/en/documents/rmp-summary/raplixa-epar-risk-management-plan-summary_en.pdf)

## Product information

Raplixa : EPAR - Product Information

English (EN) (846.12 KB - PDF)

**First published:** 04/05/2015

**Last updated:** 10/10/2018

[View](/en/documents/product-information/raplixa-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-763)

български (BG) (1.37 MB - PDF)

**First published:**

04/05/2015

**Last updated:**

10/10/2018

[View](/bg/documents/product-information/raplixa-epar-product-information_bg.pdf)

español (ES) (802.94 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

10/10/2018

[View](/es/documents/product-information/raplixa-epar-product-information_es.pdf)

čeština (CS) (1.11 MB - PDF)

**First published:**

04/05/2015

**Last updated:**

10/10/2018

[View](/cs/documents/product-information/raplixa-epar-product-information_cs.pdf)

dansk (DA) (667.49 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

10/10/2018

[View](/da/documents/product-information/raplixa-epar-product-information_da.pdf)

Deutsch (DE) (874.95 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

10/10/2018

[View](/de/documents/product-information/raplixa-epar-product-information_de.pdf)

eesti keel (ET) (792.45 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

10/10/2018

[View](/et/documents/product-information/raplixa-epar-product-information_et.pdf)

ελληνικά (EL) (1.57 MB - PDF)

**First published:**

04/05/2015

**Last updated:**

10/10/2018

[View](/el/documents/product-information/raplixa-epar-product-information_el.pdf)

français (FR) (907.5 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

10/10/2018

[View](/fr/documents/product-information/raplixa-epar-product-information_fr.pdf)

hrvatski (HR) (816.84 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

10/10/2018

[View](/hr/documents/product-information/raplixa-epar-product-information_hr.pdf)

íslenska (IS) (769.69 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

10/10/2018

[View](/is/documents/product-information/raplixa-epar-product-information_is.pdf)

italiano (IT) (811.21 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

10/10/2018

[View](/it/documents/product-information/raplixa-epar-product-information_it.pdf)

latviešu valoda (LV) (1.12 MB - PDF)

**First published:**

04/05/2015

**Last updated:**

10/10/2018

[View](/lv/documents/product-information/raplixa-epar-product-information_lv.pdf)

lietuvių kalba (LT) (903.17 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

10/10/2018

[View](/lt/documents/product-information/raplixa-epar-product-information_lt.pdf)

magyar (HU) (1.1 MB - PDF)

**First published:**

04/05/2015

**Last updated:**

10/10/2018

[View](/hu/documents/product-information/raplixa-epar-product-information_hu.pdf)

Malti (MT) (1.21 MB - PDF)

**First published:**

04/05/2015

**Last updated:**

10/10/2018

[View](/mt/documents/product-information/raplixa-epar-product-information_mt.pdf)

Nederlands (NL) (752.15 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

10/10/2018

[View](/nl/documents/product-information/raplixa-epar-product-information_nl.pdf)

norsk (NO) (739.34 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

10/10/2018

[View](/no/documents/product-information/raplixa-epar-product-information_no.pdf)

polski (PL) (1.17 MB - PDF)

**First published:**

04/05/2015

**Last updated:**

10/10/2018

[View](/pl/documents/product-information/raplixa-epar-product-information_pl.pdf)

português (PT) (675.6 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

10/10/2018

[View](/pt/documents/product-information/raplixa-epar-product-information_pt.pdf)

română (RO) (854.03 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

10/10/2018

[View](/ro/documents/product-information/raplixa-epar-product-information_ro.pdf)

slovenčina (SK) (1.16 MB - PDF)

**First published:**

04/05/2015

**Last updated:**

10/10/2018

[View](/sk/documents/product-information/raplixa-epar-product-information_sk.pdf)

slovenščina (SL) (1.09 MB - PDF)

**First published:**

04/05/2015

**Last updated:**

10/10/2018

[View](/sl/documents/product-information/raplixa-epar-product-information_sl.pdf)

Suomi (FI) (743.95 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

10/10/2018

[View](/fi/documents/product-information/raplixa-epar-product-information_fi.pdf)

svenska (SV) (786.13 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

10/10/2018

[View](/sv/documents/product-information/raplixa-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IB/0021/G 19/03/2018

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Raplixa : EPAR - All Authorised presentations

English (EN) (467.44 KB - PDF)

**First published:** 04/05/2015

**Last updated:** 10/10/2018

[View](/en/documents/all-authorised-presentations/raplixa-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-584)

български (BG) (495.82 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

10/10/2018

[View](/bg/documents/all-authorised-presentations/raplixa-epar-all-authorised-presentations_bg.pdf)

español (ES) (458.22 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

10/10/2018

[View](/es/documents/all-authorised-presentations/raplixa-epar-all-authorised-presentations_es.pdf)

čeština (CS) (486.16 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

10/10/2018

[View](/cs/documents/all-authorised-presentations/raplixa-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (473.24 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

10/10/2018

[View](/da/documents/all-authorised-presentations/raplixa-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (486.73 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

10/10/2018

[View](/de/documents/all-authorised-presentations/raplixa-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (457.96 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

10/10/2018

[View](/et/documents/all-authorised-presentations/raplixa-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (522.16 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

10/10/2018

[View](/el/documents/all-authorised-presentations/raplixa-epar-all-authorised-presentations_el.pdf)

français (FR) (458.01 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

10/10/2018

[View](/fr/documents/all-authorised-presentations/raplixa-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (480.96 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

10/10/2018

[View](/hr/documents/all-authorised-presentations/raplixa-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (484.51 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

10/10/2018

[View](/is/documents/all-authorised-presentations/raplixa-epar-all-authorised-presentations_is.pdf)

italiano (IT) (485.25 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

10/10/2018

[View](/it/documents/all-authorised-presentations/raplixa-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (489.37 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

10/10/2018

[View](/lv/documents/all-authorised-presentations/raplixa-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (473.19 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

10/10/2018

[View](/lt/documents/all-authorised-presentations/raplixa-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (476.56 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

10/10/2018

[View](/hu/documents/all-authorised-presentations/raplixa-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (509.39 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

10/10/2018

[View](/mt/documents/all-authorised-presentations/raplixa-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (458.08 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

10/10/2018

[View](/nl/documents/all-authorised-presentations/raplixa-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (457.37 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

10/10/2018

[View](/no/documents/all-authorised-presentations/raplixa-epar-all-authorised-presentations_no.pdf)

polski (PL) (485.34 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

10/10/2018

[View](/pl/documents/all-authorised-presentations/raplixa-epar-all-authorised-presentations_pl.pdf)

português (PT) (901.52 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

10/10/2018

[View](/pt/documents/all-authorised-presentations/raplixa-epar-all-authorised-presentations_pt.pdf)

română (RO) (48.88 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

10/10/2018

[View](/ro/documents/all-authorised-presentations/raplixa-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (478.28 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

10/10/2018

[View](/sk/documents/all-authorised-presentations/raplixa-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (476.99 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

10/10/2018

[View](/sl/documents/all-authorised-presentations/raplixa-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (457.79 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

10/10/2018

[View](/fi/documents/all-authorised-presentations/raplixa-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (21.78 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

10/10/2018

[View](/sv/documents/all-authorised-presentations/raplixa-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Raplixa Active substance

- human fibrinogen
- human thrombin

International non-proprietary name (INN) or common name

- human fibrinogen
- human thrombin

Therapeutic area (MeSH) Hemostasis, Surgical Anatomical therapeutic chemical (ATC) code B02BC30

### Pharmacotherapeutic group

Antihemorrhagics

### Therapeutic indication

Supportive treatment where standard surgical techniques are insufficient for improvement of haemostasis.

Raplixa must be used in combination with an approved gelatin sponge.

Raplixa is indicated in adults over 18 years of age.

## Authorisation details

EMA product number EMEA/H/C/002807 Marketing authorisation holder

Mallinckrodt Pharmaceuticals Ireland Limited

College Business  Technology Park

Marketing authorisation issued 19/03/2015 Withdrawal of marketing authorisation 19/03/2018 Revision 6

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Raplixa : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (586.53 KB - PDF)

**First published:** 14/01/2016

**Last updated:** 10/10/2018

[View](/en/documents/procedural-steps-after/raplixa-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Raplixa : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/747327/2014

English (EN) (3.13 MB - PDF)

**First published:** 04/05/2015

**Last updated:** 10/10/2018

[View](/en/documents/assessment-report/raplixa-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Raplixa

Adopted

Reference Number: EMA/CHMP/197/2015

English (EN) (527.74 KB - PDF)

**First published:** 23/01/2015

**Last updated:** 10/10/2018

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-raplixa_en.pdf)

#### News on Raplixa

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 January 2015](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-january-2015) 23/01/2015

**This page was last updated on** 10/10/2018

## Share this page

[Back to top](#main-content)